TerminatedPhase NAResults posted

Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients

Lead sponsor

The Cleveland Clinic

Asset

Rivastigmine

Listed sites

Recruiting sites

Enrollment

actual

Study population

MCI / preclinical Alzheimer’s

Key I/E criterion

•Age 55-85

Primary endpoint

•BOLD Response on Functional Magnetic Resonance Imaging (fMRI)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAG022304

NCT IDNCT01602198

Timeline

Milestones

Study start2011-06 (month precision)

Study first posted2012-05-18estimated

Primary completion2013-01actual (month precision)

Study completion2013-01actual (month precision)

Last update posted2017-02-28actual

Results first posted2017-02-28actual

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

MCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age55 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of amnestic MCI

•In good general health with no diseases expected to interfere with the study

•Ability to undergo MRI

•Fluent in English

•Stable prescription dosages 1 month prior to testing

•Carrier of the APOE e4 allele (determined by blood draw at screening visit)

Exclusion criteria

•Neurological illness/conditions

•Medical illnesses/conditions that may affect brain function

•Prior history of use of any cholinesterase inhibitor

•Instable or severe cardiovascular disease or asthmatic condition

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Neuroimaging

2 endpoints

Primary/protocol endpoint

Change in BOLD Response on Functional Magnetic Resonance Imaging (fMRI)

Time frame:baseline and 6 months

change from baseline, improvement

Primary/registry result

Change in BOLD Response on Functional Magnetic Resonance Imaging (fMRI)

Time frame:baseline and 6 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.